Achaogen Inc (NASDAQ:AKAO) – Research analysts at Wedbush issued their Q1 2018 EPS estimates for Achaogen in a report issued on Wednesday, according to Zacks Investment Research. Wedbush analyst R. Driscoll anticipates that the biopharmaceutical company will earn ($0.94) per share for the quarter. Wedbush currently has a “Outperform” rating and a $22.00 target price on the stock. Wedbush also issued estimates for Achaogen’s Q2 2018 earnings at ($0.96) EPS, Q3 2018 earnings at ($0.82) EPS, Q4 2018 earnings at ($0.81) EPS, FY2018 earnings at ($3.53) EPS, FY2019 earnings at ($2.99) EPS, FY2020 earnings at ($2.78) EPS, FY2021 earnings at ($2.79) EPS and FY2022 earnings at ($1.62) EPS.
Several other equities analysts have also recently issued reports on the company. Leerink Swann reissued an “outperform” rating on shares of Achaogen in a report on Sunday, March 4th. William Blair reissued an “outperform” rating on shares of Achaogen in a report on Wednesday, February 28th. HC Wainwright reduced their price target on Achaogen from $31.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, March 1st. Stifel Nicolaus reduced their price target on Achaogen from $27.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 price target (down previously from $29.00) on shares of Achaogen in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $24.10.
Shares of Achaogen (NASDAQ:AKAO) traded up $0.07 during mid-day trading on Monday, hitting $11.57. The stock had a trading volume of 678,474 shares, compared to its average volume of 1,193,718. The firm has a market cap of $495.58, a PE ratio of -3.64 and a beta of 1.28. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of 0.08. Achaogen has a fifty-two week low of $9.83 and a fifty-two week high of $27.49.
Achaogen (NASDAQ:AKAO) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.21). The company had revenue of $1.87 million during the quarter, compared to analyst estimates of $1.18 million. Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%.
Large investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC purchased a new stake in Achaogen during the 4th quarter worth approximately $151,000. Clear Harbor Asset Management LLC purchased a new stake in Achaogen during the 4th quarter worth approximately $177,000. Ellington Management Group LLC purchased a new stake in Achaogen during the 4th quarter worth approximately $177,000. Tower Research Capital LLC TRC increased its stake in Achaogen by 375.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,648 shares of the biopharmaceutical company’s stock worth $201,000 after buying an additional 14,725 shares in the last quarter. Finally, California Public Employees Retirement System purchased a new stake in Achaogen during the 2nd quarter worth approximately $243,000. Institutional investors own 77.37% of the company’s stock.
In other news, major shareholder Robert W. Duggan acquired 15,000 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was bought at an average cost of $10.89 per share, for a total transaction of $163,350.00. Following the purchase, the insider now owns 5,617,752 shares in the company, valued at $61,177,319.28. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Robert W. Duggan acquired 20,000 shares of the business’s stock in a transaction on Monday, March 12th. The shares were purchased at an average price of $11.39 per share, with a total value of $227,800.00. Following the completion of the purchase, the insider now owns 6,255,148 shares in the company, valued at approximately $71,246,135.72. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 787,408 shares of company stock valued at $8,355,686 and sold 7,354 shares valued at $78,467. Corporate insiders own 8.36% of the company’s stock.
WARNING: This article was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/14/achaogen-inc-to-post-q1-2018-earnings-of-0-94-per-share-wedbush-forecasts-akao.html.
Achaogen Company Profile
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.